Detail akcie BttrLife Pharma Rg online

Business Summary: BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical, is a non-hallucinogenic second-generation lysergic acid diethylamide (LSD) derivative molecule that mimics the projected therapeutic potential of LSD in the treatment of disorders, such as depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical, is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound, with the potential for treatment of anxiety related disorders, including benzodiazepine dependency. It is also refining and developing drug candidates from a set of complementary interferon-based technologies, which have the potential to engage the immune system to fight viral infections.
Financial Summary: BRIEF: For the nine months ended 31 October 2025, BetterLife Pharma Inc revenues was not reported. Net loss decreased 60% to C$1.1M. Lower net loss reflects development and commercialization of patented, differentiate segment loss decrease of 70% to C$1.3M, Canada segment loss decrease of 82% to C$745K. Basic Earnings per Share excluding Extraordinary Items increased from -C$0.02 to -C$0.01.